Many people and families are surprised to learn that stopping benzodiazepines can cause serious withdrawal, including seizures. This article explains how and why seizures can happen during withdrawal, who is at higher risk, and why supervised detox and individualized tapering are safer than stopping suddenly. This is general educational information and not individualized medical advice. Placement and medication decisions require assessment by a qualified clinician.

How benzodiazepine withdrawal can lead to seizures

Benzodiazepines are central nervous system depressants that increase the brain chemical activity of GABA, which calms excessive neuronal firing. After regular use, the brain adapts, and sudden reduction or abrupt stopping can leave a relative excess of excitatory activity. That rebound can produce anxiety, tremor, and in more severe cases, convulsions or status epilepticus. Health authorities warn that abrupt discontinuation or rapid dose reduction can precipitate life threatening reactions including seizures. FDA: Benzodiazepine safety communication.

What the evidence and guidance say

  • The U.S. Food and Drug Administration recommends against abrupt discontinuation and advises a gradual, patient specific taper. FDA.
  • A recent joint clinical practice guideline recommends individualized tapering, starting conservatively (for many patients 5 to 10 percent dose reductions every 2 to 4 weeks) and adjusting pace based on symptoms. The guideline emphasizes monitoring for withdrawal signs and pausing or slowing a taper when needed. Joint Clinical Practice Guideline on Benzodiazepine Tapering.
  • Reviews of withdrawal seizures list major risk factors and call for caution in patients with prior seizures, unstable medical illness, or concurrent alcohol or sedative use. Withdrawal seizures: possible risk factors.

Who is at higher risk of benzodiazepine withdrawal seizures?

Risk is not the same for everyone. Common, evidence-supported risk factors include:

  • Long duration of regular benzodiazepine use, or high daily dose. Joint Guideline.
  • Short-acting benzodiazepines like alprazolam tend to produce earlier and sometimes more intense rebound symptoms compared with longer-acting agents. Joint Guideline.
  • History of epilepsy or prior withdrawal seizures. PubMed review.
  • Concurrent heavy alcohol use or recent alcohol withdrawal, and use of other medicines that lower the seizure threshold or depress breathing. SAMHSA TIP 45 – Detoxification.
  • Older age, medical or psychiatric comorbidity, or taking multiple interacting medications. Joint Guideline.

Symptoms and timing to watch for

Withdrawal timing depends on the specific benzodiazepine used. Short-acting medications often produce rebound symptoms within 1 to 4 days, while long-acting agents may produce withdrawal effects later, often 4 to 10 days after the last dose. Symptoms range from mild anxiety and insomnia to tremor, autonomic instability and, in severe cases, seizures or delirium. If someone develops shaking that is not explained by other causes, loss of awareness, or unusual movements, seek urgent medical evaluation.

Setting Typical monitoring Who it is usually for Pros Cons
Outpatient supervised taper Regular clinician visits, symptom monitoring, medication adjustments, family education Patients without prior seizures, stable medical/psychiatric status, reliable supports Least disruptive, preserves daily life, individualized pace Requires reliable follow up and adherence
Inpatient medically supervised detox 24 hour nursing, frequent vital signs, rapid medication adjustment, access to emergent care History of withdrawal seizures, active alcohol or sedative misuse, severe medical or psychiatric comorbidity Higher monitoring, rapid treatment for seizures or delirium More costly, more disruptive to routine

Why supervised detox or tapering matters

Supervision reduces risk in several ways. Clinicians can:

  • Create an individualized taper plan based on dose, benzodiazepine half-life, medical history and patient preference. Joint Guideline.
  • Switch, when appropriate, to a longer-acting benzodiazepine to smooth blood levels and reduce rebound, or select other medically supported strategies. This decision should be patient specific. Joint Guideline.
  • Monitor for and treat emergent withdrawal symptoms, including giving additional benzodiazepine doses when medically indicated, or transferring to inpatient care if seizures or delirium develop. SAMHSA TIP 45.
  • Identify and manage other factors that raise seizure risk such as alcohol use, interacting medications, or electrolyte disturbance. PubMed review.

Medications and approaches sometimes used

There is no single universally accepted medication regimen for all patients. Common clinical approaches include gradual dose reduction of the current benzodiazepine, substitution with a longer-acting agent for the taper when appropriate, and slow, individualized reductions guided by symptoms. The strength of evidence for adjunctive non-benzodiazepine medications to reduce withdrawal symptoms is limited, and choices should be made by clinicians familiar with the patient. Joint Guideline, management review.

When inpatient care or urgent evaluation is needed

Inpatient medically supervised withdrawal is often recommended for people at higher risk, including those with a history of withdrawal seizures, active heavy alcohol or sedative use, unstable medical or psychiatric illness, or if social supports and reliable outpatient follow up are lacking. Inpatient settings provide continuous monitoring and immediate treatment if a seizure or delirium occurs. SAMHSA TIP 45.

Safety callout: If someone is having a medical emergency, including a seizure, call 911 immediately. For a mental health or suicide crisis, call or text 988 for the 988 Suicide & Crisis Lifeline. If you are in doubt about severity, seek emergency care right away.

What families can do right now

  • Do not stop a benzodiazepine suddenly without medical supervision. Contact the prescriber or a clinician to arrange an individualized taper plan. FDA.
  • Provide information to clinicians about exact medications, doses, timing and any history of seizures or heavy alcohol use.
  • Arrange close follow up and ensure someone can bring the person to the emergency department if alarming symptoms appear.
  • Consider treatment settings that match the risk level – outpatient supervised taper for lower risk patients, inpatient detox for higher risk cases. SAMHSA TIP 45.

Frequently asked questions

Can benzodiazepine withdrawal be fatal?

Severe withdrawal can be life threatening if it progresses to status epilepticus or severe autonomic instability. Those outcomes are uncommon when tapering is supervised, but the risk is higher with abrupt cessation or when other risks are present. FDA.

Is a longer taper always safer?

Longer, slower tapers are often better tolerated, but there is no single schedule for everyone. The joint guidance recommends tailoring the taper and monitoring symptoms closely; many patients do well with small percentage reductions every 2 to 4 weeks, adjusted to individual response. Joint Guideline.

What if someone is pregnant or an adolescent?

Pregnancy and adolescence are higher risk situations needing specialist care. Do not attempt to stop benzodiazepines without urgent consultation from clinicians experienced in perinatal or adolescent addiction and psychiatric care.

Sources and further reading

Next steps, and how we can help

If you or a loved one are taking benzodiazepines and want safe help reducing dose, speak with a clinician who treats substance dependence or a prescriber experienced in benzodiazepine tapers. If you are evaluating care options, review available treatments and locations on our site and contact us to discuss a confidential assessment: see our treatments, locations, and contact page. Placement and medication planning should be individualized by a qualified clinician.

Remember, if someone is having a seizure or another medical emergency, call 911. For a mental health or suicide crisis, call or text 988.